Equity research analysts and institutional forecasters maintain a stable long-term outlook for Kenvue (NYSE: KVUE), driven by its robust portfolio of household consumer health brands like Tylenol, Neutrogena, and Listerine. Market evaluations highlight the company's defensive characteristics, consistent cash flow generation, and reliable dividend distributions, balancing these positive attributes against broader consumer spending trends and foreign exchange currency volatility across global retail markets.